Skip Navigation Archive: U.S. Department of Health and Human Services U.S. Department of Health and Human Services
Archive: Agency for Healthcare Research Quality www.ahrq.gov
Archival print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

  • Publication # 14-RA001

New review evaluates strategies for predicting and preventing stroke in atrial fibrillation patients

Comparative Effectiveness Research

A new research review by AHRQ's Effective Health Care Program compares tools that evaluate stroke risk factors and available therapies for patients with atrial fibrillation, the most common cardiac arrhythmia seen in clinical practice. Patients with atrial fibrillation have a five-fold increased risk of stroke. It is estimated that up to 25 percent of all strokes in the elderly are a consequence of atrial fibrillation and that these strokes cost Medicare approximately $8 billion annually. 

The review finds that, in patients with atrial fibrillation, CHADS2 and CHA2DS2-VASc scores have the greatest discrimination for stroke events among the risk scores reviewed, whereas HAS-BLED provides the best discrimination of bleeding risk. However, additional information is needed to determine how scores should be utilized in clinical practice. 

According to the review, initial trials of newer oral anticoagulants, including apixaban and higher-dose dabigatran, show a high strength of evidence for reducing stroke and bleeding events compared with warfarin in patients with atrial fibrillation, though no studies directly compare the new therapies. In addition, the review finds that for patients not suitable for oral anticoagulation therapies, apixaban is more effective and has a better safety and tolerability profile than aspirin in stroke prevention. However, additional studies are required for common clinical scenarios encountered with patients on therapies for stroke prevention, including strategies for patients undergoing invasive procedures, switching among anticoagulant therapies, and starting or restarting anticoagulant therapy in patients with previous major bleeding events. 

These findings and others can be found in the research review Stroke Prevention in Atrial Fibrillation at http://go.usa.gov/DX7H.

Page last reviewed October 2013
Internet Citation: New review evaluates strategies for predicting and preventing stroke in atrial fibrillation patients: Comparative Effectiveness Research. October 2013. Agency for Healthcare Research and Quality, Rockville, MD. https://archive.ahrq.gov/news/newsletters/research-activities/13oct/1013RA20.html

 

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care